Analysts Offer Predictions for Editas Medicine FY2026 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Editas Medicine in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will earn ($0.89) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Editas Medicine's current full-year earnings is ($2.71) per share.

EDIT has been the topic of a number of other research reports. Wall Street Zen raised Editas Medicine from a "sell" rating to a "hold" rating in a research note on Wednesday, May 14th. HC Wainwright began coverage on shares of Editas Medicine in a research report on Monday, April 28th. They set a "buy" rating and a $3.00 price target on the stock. Finally, Robert W. Baird lowered their price objective on shares of Editas Medicine from $8.00 to $4.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, two have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Editas Medicine presently has a consensus rating of "Hold" and an average price target of $5.36.

Editas Medicine Price Performance

Shares of NASDAQ:EDIT traded down $0.21 during trading on Tuesday, reaching $1.97. The stock had a trading volume of 3,047,521 shares, compared to its average volume of 2,578,978. The stock has a market capitalization of $164.91 million, a PE ratio of -0.77 and a beta of 2.10. Editas Medicine has a 52 week low of $0.91 and a 52 week high of $6.05. The business's 50-day moving average price is $1.54 and its 200 day moving average price is $1.52.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The firm had revenue of $4.66 million for the quarter, compared to analyst estimates of $0.79 million. Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. During the same period in the previous year, the business earned ($76.00) earnings per share.

Insider Activity

In other Editas Medicine news, CEO Gilmore Neil O'neill sold 15,192 shares of the company's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $1.72, for a total transaction of $26,130.24. Following the completion of the sale, the chief executive officer now owns 280,282 shares in the company, valued at approximately $482,085.04. The trade was a 5.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 16,364 shares of company stock valued at $28,146. 2.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Editas Medicine

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ieq Capital LLC bought a new position in Editas Medicine during the fourth quarter worth about $31,000. Dark Forest Capital Management LP increased its stake in shares of Editas Medicine by 66.9% in the 4th quarter. Dark Forest Capital Management LP now owns 32,787 shares of the company's stock valued at $42,000 after acquiring an additional 13,138 shares during the last quarter. Brave Asset Management Inc. raised its position in shares of Editas Medicine by 250.0% in the 1st quarter. Brave Asset Management Inc. now owns 35,000 shares of the company's stock valued at $41,000 after acquiring an additional 25,000 shares during the period. SCS Capital Management LLC bought a new position in Editas Medicine during the 1st quarter worth approximately $41,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in Editas Medicine by 45.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 35,781 shares of the company's stock worth $40,000 after acquiring an additional 11,252 shares during the last quarter. Institutional investors own 71.90% of the company's stock.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.